论文部分内容阅读
目的 研究淋巴瘤初诊时患者血清乳酸脱氢酶（Ｓ－ＬＤ）、血清β２－微球蛋白（Ｓ－β２Ｍ）和尿β２－微球蛋白（Ｕ－β２Ｍ） 判断淋巴瘤预后的价值。方法回顾分析１１０例经病理确诊的淋巴瘤患者，初诊时Ｓ－ＬＤ、Ｓ－β２Ｍ和Ｕ－β２Ｍ水平与临床特点 及治疗效果的关系。结果 淋巴瘤患者三个指标均明显高于对照组。非霍奇金淋巴瘤（ＮＨＬ）三个指标高于霍奇金淋巴瘤 （ＨＤ），骨髓侵犯率也增高，对治疗的反应性则降低。结论初诊时，Ｓ－ＬＤ、Ｓ－β２Ｍ和Ｕ－β２Ｍ水平是淋巴瘤有意义的预后指 标。联合Ｓ－ＬＤ和Ｓ－β２Ｍ判断淋巴瘤预后更有价值。
Objective To investigate the prognostic value of serum lactate dehydrogenase (S-LD), serum β2-microglobulin (S-β2M) and urinary β2-microglobulin (U-β2M) in lymphoma patients with newly diagnosed lymphoma. Methods A retrospective analysis of 110 cases of pathologically diagnosed lymphoma patients, the initial diagnosis of S-LD, S-β2M and U-β2M levels and clinical features and treatment of the relationship. Results Three indicators of lymphoma patients were significantly higher than the control group. Non-Hodgkin’s lymphoma (NHL) three indicators higher than Hodgkin’s lymphoma (HD), bone marrow infiltration rate is also increased, the response to treatment is reduced. Conclusion The initial diagnosis, S-LD, S-β2M and U-β2M levels of lymphoma is a meaningful prognostic indicator. Joint S-LD and S-β2M lymphoma prognosis of more value.